Cyprotex PLC Launch of new cardiotoxicity service-eCiphrCardio
February 14 2013 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
14 February 2013
Cyprotex launches a new cardiotoxicity service -
eCiphrCardio
14 February, 2013 - Cyprotex PLC (AIM:CRX), the specialist
preclinical contract research organisation (CRO), today announces
the launch of eCiphrCardio, an assay to assess potential
cardiotoxicity of compounds in early drug development. This assay
is based on microelectrode array (MEA) technology.
Cardiotoxicity continues to be one of the main toxicological
reasons for drug attrition during the drug development process.
eCiphrCardio is a high throughput in vitro assay used to screen
compounds to detect any potentially adverse effects on cardiac
function and is available on the Maestro MEA system from Axion
Biosystems ("Axion"). The MEA Maestro system has proven to be a
robust, high-throughput platform to test for drug effects on
clinically-relevant cardiac electrophysiological features. This new
assay complements our existing CellCiphr(R) Premier assay which is
used to screen compounds for the potential for drug-induced
hepatotoxicity.
Dr. Anthony Baxter, the Chief Executive Officer of Cyprotex,
said: "Screening for drug-induced cardiotoxicity continues to be a
major requirement by the regulatory agencies. eCiphrCardio
complements our comprehensive portfolio of assays to address
potential toxicity concerns early in the drug development process.
It improves the prediction of cardiotoxicity by providing relevant
mechanistic insights. We are now applying the MEA system for
additional applications including the development of a new
neurotoxicity screen, expected to be launched in the near
future."
Tom O'Brien, President and Chief Executive Officer of Axion,
added: "Cardiac assays using single-well MEA systems have been
validated in academic studies for more than a decade, so the
predictive value of this in vitro assay is firmly established. With
the introduction of eCiphrCardio, Cyprotex is the first to offer
this assay on our high throughput platform. By capturing the power
of multiwell MEA technology, Cyprotex has made MEA assays practical
for use in early stage drug development. We look forward to working
with this team as they expand their portfolio of cellular
electrophysiology assays utilising Axion's Maestro MEA system."
To find out more about this service, visit:
http://www.cyprotex.com/eCiphrCardio
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief ir@cyprotex.com
Executive Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker Tel: +44 (0)20
to Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@nplus1singer.com
Jenny Wyllie jenny.wyllie@nplus1singer.com
www.nplus1singer.com
FTI Consulting Tel: +44 (0) 20
7831 3113
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK,
and Watertown, MA in the US and is listed on the AIM market of the
London Stock Exchange (CRX). The company was established in 1999
and works with more than 700 partners ranging from small biotechs
to large pharma companies. Cyprotex acquired Apredica and the
assets of Cellumen Inc. in August 2010 and the combined business
provides support for a wide range of experimental and computational
ADME-Tox and PK services, extending from early drug discovery
through to IND submission. The company's core capabilities include
high quality in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services and
predictive modelling using PBPK and QSAR techniques, including
Cloe(R) PK for in vivo PK prediction. For more information, see
www.cyprotex.com.
About Axion BioSystems, Inc.
Axion BioSystems, Inc. is a life science instrumentation company
that develops high-throughput microelectrode array (MEA) systems
for in vitro network electrophysiology, allowing researchers to
model neural activity and cardiac beating. As a result, toxicity
and efficacy can be assessed earlier in the drug development
process with greater sensitivity and accuracy. For more
information, see www.axionbiosystems.com.
Further information on eCiphrCardio(R)
eCiphrCardio is a high throughput in vitro assay used to screen
compounds to detect any potentially adverse effects on cardiac
function. The assay has been validated with Cellular Dynamics
International's human induced pluripotent stem (iPS) cell-derived
iCell(R) Cardiomyocytes, which are plated on Axion BioSystem's
Maestro MEA system. CDI's iCell(R) Cardiomyocytes are highly pure,
fully-functional human cardiac cells manufactured in reproducibly
high quality and quantity to provide a more reliable, relevant and
predictive in vitro model. The MEA Maestro system has proven to be
a robust, high-throughput system to test for drug effects on
clinically-relevant cardiac electrophysiological features,
including beat rate, QT interval, amplitude, and conduction
velocity.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUORBROWAUAAR
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024